Aerin Medical Achieves Milestone of Treating Over 200,000 Patients with Its Minimally Invasive Therapies for Chronic Nasal Disorders
Aerin Medical Inc., a recognized innovator in minimally invasive therapies for chronic nasal conditions, has announced a major milestone in its clinical and commercial journey. The company revealed that more than 200,000 patients worldwide have now been treated using its proprietary RhinAer and VivAer technologies. This achievement highlights the growing adoption of these advanced, minimally invasive treatment options among physicians and underscores their expanding role in addressing chronic nasal disorders.
The milestone reflects increasing real-world utilization of Aerin’s temperature- and impedance-controlled radiofrequency platforms, which are designed to deliver targeted therapy for patients suffering from chronic rhinitis (CR) and nasal airway obstruction (NAO). These conditions affect millions of individuals globally and are often associated with symptoms such as persistent nasal congestion, runny nose, and impaired breathing. Traditional treatment options, including medications or more invasive surgical procedures, do not always provide lasting relief or may carry higher risks. Against this backdrop, Aerin’s technologies have emerged as practical alternatives that bridge the gap between conservative therapy and surgery.
The RhinAer system is specifically designed to treat chronic rhinitis by targeting the posterior nasal nerve region, which plays a key role in regulating nasal secretions. By applying controlled radiofrequency energy, the device disrupts overactive neural pathways responsible for excessive mucus production, thereby reducing symptoms such as rhinorrhea and postnasal drip. On the other hand, VivAer focuses on improving nasal airflow in patients with nasal airway obstruction. It works by remodeling the nasal valve area, a common site of obstruction, using controlled energy delivery to gently reshape tissue and enhance airflow without the need for invasive surgery.
The growing use of these technologies among ear, nose, and throat (ENT) specialists—also known as otolaryngologists—demonstrates a shift in clinical practice toward minimally invasive, office-based procedures. Physicians are increasingly incorporating RhinAer and VivAer into their treatment algorithms for CR and NAO, recognizing their ability to deliver effective symptom relief with reduced downtime and improved patient convenience. This trend is further supported by the scalability of these procedures, which can often be performed in outpatient settings without the need for general anesthesia.
In addition to widespread clinical adoption, Aerin Medical has built a substantial body of scientific evidence supporting the safety and effectiveness of its technologies. Clinical studies involving nearly 1,000 patients across multiple countries have evaluated the performance of RhinAer and VivAer. These studies have consistently demonstrated statistically significant improvements in key symptom scores, as well as durable outcomes that persist over time. Such findings are critical in establishing physician confidence and driving broader acceptance within the medical community.
The company’s commitment to evidence generation is also reflected in its extensive publication record. Research related to Aerin’s technologies has been featured in more than 40 peer-reviewed publications, further validating their clinical utility. These publications provide detailed insights into patient outcomes, procedural techniques, and long-term benefits, contributing to a growing knowledge base that informs best practices in the treatment of chronic nasal conditions.
Beyond clinical evidence, this milestone underscores Aerin’s ongoing efforts to expand patient access to innovative care. By working closely with healthcare providers, the company aims to ensure that more patients who may benefit from minimally invasive procedures are identified and treated appropriately. Increased awareness among both physicians and patients has played a key role in driving adoption, as individuals seek alternatives that offer effective relief without the burden of more invasive interventions.
Commenting on the achievement, Matt Brokaw, President and Chief Executive Officer of Aerin Medical, emphasized the collaborative nature of the company’s success. He highlighted the essential role of physician partnerships in advancing both product development and clinical validation. According to Brokaw, close collaboration with otolaryngologists has enabled the company to design innovative technologies that address real-world clinical needs while also supporting the execution of rigorous clinical studies.
He further noted that this partnership-driven approach has been instrumental in translating research into practice, ultimately expanding access to effective treatments for patients with chronic nasal conditions. For Aerin Medical, the milestone of treating over 200,000 patients is not only a reflection of past achievements but also a source of motivation for future innovation and growth.
Importantly, the company remains focused on placing patients and physicians at the center of its mission. By prioritizing patient outcomes and physician experience, Aerin continues to refine its technologies and broaden their applicability. The milestone serves as a testament to the impact that targeted innovation, supported by strong clinical evidence, can have on improving quality of life for patients dealing with chronic and often debilitating nasal conditions.
As the demand for minimally invasive solutions continues to rise, Aerin Medical is well positioned to maintain its leadership in this space. With a solid foundation of clinical data, a growing network of physician adopters, and a clear commitment to innovation, the company is poised to further transform the standard of care for chronic rhinitis and nasal airway obstruction in the years ahead.
About VivAer
VivAer is a minimally invasive technology that uses patented, temperature- and impedance-controlled radiofrequency energy and is clinically demonstrated to provide long-term relief from nasal obstruction. VivAer features a thin, wand-like stylus that attaches to an Aerin console. The stylus is inserted via the nostril to gently remodel the nasal tissue and improve airflow. VivAer does not involve cutting, removal of nasal tissue or bone, or the use of an implant. The procedure is performed in-office under local anesthesia, with no incisions and minimal downtime. The VivAer Stylus received CE Mark in 2016 and FDA 510(k) clearance in December 2017. For more information, visit www.VivAer.com.
About RhinAer
RhinAer is a minimally invasive technology that uses patented, temperature- and impedance-controlled radiofrequency energy and is clinically demonstrated to provide long-term relief from chronic rhinitis. RhinAer features a thin, wand-like stylus that attaches to an Aerin console. The stylus is inserted via the nostril to deliver precise therapeutic benefits to the posterior nasal nerve (PNN) and soft tissue, while sparing surrounding tissues. RhinAer directly disrupts the PNN that triggers excessive mucus production, treating an underlying cause of chronic rhinitis.
RhinAer provides ENT physicians with a comprehensive solution for the treatment of chronic rhinitis, addressing sources of rhinorrhea and congestion. The procedure can be performed with a local anesthetic during an office visit, with no incisions, and minimal downtime. RhinAer received FDA 510(k) clearance in December 2019 and CE Mark in 2020. For more information, visit www.RhinAer.com.
About Aerin Medical
Aerin Medical is a privately held, venture-backed company, headquartered in Mountain View, California. Aerin’s mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company’s products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin’s proprietary temperature- and impedance-controlled technology, which allows ENT physicians to reliably improve patients’ symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 200,000 patients have been treated with Aerin Medical products to date.
Source Linkl:https://www.businesswire.com/
